Biomarkers stewardship in parkinsonism: integrating alpha-synuclein seed amplification assays and neurofilament light chain into diagnostic pathways and patient communication
Vincent Leclercq · 2026
Read Biomarkers stewardship in parkinsonism: integrating alpha-synuclein seed amplification assays and neurofilament light chain into diagnostic pathways and patient communication by Vincent Leclercq (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13269519.txt.
Description
Vincent Leclercq published a review article in 2026 on careful use of two biomarker tests in parkinsonism, a group of movement disorders that can look alike early on. One test detects clumping activity of a brain protein, alpha-synuclein. The other measures a protein released when nerve fibers are damaged.
The first test identifies Parkinson's disease and Lewy body dementia with high accuracy, but misses more cases in some genetic and early forms. The second test helps separate those diseases from atypical disorders, though cut points vary with age and test platform. Leclercq proposes step-by-step paths that combine test results with scans, genes, and prior likelihood. He also stresses explaining positive and negative results clearly to patients.
Catalog record
| CREATOR | Vincent Leclercq |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79805 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |